Table 4 Tumor responses assessed by investigator
Group | |||||||
|---|---|---|---|---|---|---|---|
1 0 mg/qd | 200 mg/qd | 300 mg/qd | 450 mg/qd | 600 mg/qd | 800 mg/qd | Total | |
(n = 4) | (n = 3) | (n = 3) | (n = 4) | (n = 3) | (n = 3) | (N = 20) | |
Partial remission (PR) | 0 | 0 | 0 | 0 | 0 | 1 (33.3%) | 1 (5.3%) |
Stable disease (SD) | 0 | 2 (66.7%) | 2 (66.7%) | 2 (50.0%) | 2 (66.7%) | 2 (66.7%) | 10 (52.6%) |
Progressive disease (PD) | 3 (100.0%) | 1 (33.3%) | 1 (33.3%) | 2 (50.0%) | 1 (33.3%) | 0 | 8 (42.1%) |
Total | 3 (100.0%) | 3 (100.0%) | 3 (100.0%) | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 19 (100.0%) |
Missing | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Objective remission rate, % (95%CI) | 0 (NA, NA) | 0 (NA, NA) | 0 (NA, NA) | 0 (NA, NA) | 0 (NA, NA) | 33.3 (0.84, 90.57) | 5.3 (0.13, 26.03) |
Disease control rate, % (95%CI) | 0 (NA, NA) | 66.7 (9.43, 99.16) | 66.7 (9.43, 99.16) | 50.0 (6.76, 93.24) | 66.7 (9.43, 99.16) | 100.0(29.24,100.0) | 57.9 (33.50, 79.75) |